Literature DB >> 11222689

Protection from Ebola virus mediated by cytotoxic T lymphocytes specific for the viral nucleoprotein.

J A Wilson1, M K Hart.   

Abstract

Cytotoxic T lymphocytes (CTLs) are proposed to be critical for protection from intracellular pathogens such as Ebola virus. However, there have been no demonstrations that protection against Ebola virus is mediated by Ebola virus-specific CTLs. Here, we report that C57BL/6 mice vaccinated with Venezuelan equine encephalitis virus replicons encoding the Ebola virus nucleoprotein (NP) survived lethal challenge with Ebola virus. Vaccination induced both antibodies to the NP and a major histocompatibility complex class I-restricted CTL response to an 11-amino-acid sequence in the amino-terminal portion of the Ebola virus NP. Passive transfer of polyclonal NP-specific antiserum did not protect recipient mice. In contrast, adoptive transfer of CTLs specific for the Ebola virus NP protected unvaccinated mice from lethal Ebola virus challenge. The protective CTLs were CD8(+), restricted to the D(b) class I molecule, and recognized an epitope within amino acids 43 to 53 (VYQVNNLEEIC) in the Ebola virus NP. The demonstration that CTLs can prevent lethal Ebola virus infection affects vaccine development in that protective cellular immune responses may be required for optimal protection from Ebola virus.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11222689      PMCID: PMC115890          DOI: 10.1128/JVI.75.6.2660-2664.2001

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  18 in total

Review 1.  Quantitative aspects of T cell activation--peptide generation and editing by MHC class I molecules.

Authors:  S Stevanović; H Schild
Journal:  Semin Immunol       Date:  1999-12       Impact factor: 11.130

2.  Priming of anti-human immunodeficiency virus (HIV) CD8+ cytotoxic T cells in vivo by carrier-free HIV synthetic peptides.

Authors:  M K Hart; K J Weinhold; R M Scearce; E M Washburn; C A Clark; T J Palker; B F Haynes
Journal:  Proc Natl Acad Sci U S A       Date:  1991-11-01       Impact factor: 11.205

3.  Immunization for Ebola virus infection.

Authors:  L Xu; A Sanchez; Z Yang; S R Zaki; E G Nabel; S T Nichol; G J Nabel
Journal:  Nat Med       Date:  1998-01       Impact factor: 53.440

4.  Molecular analyses of a five-amino-acid cytotoxic T-lymphocyte (CTL) epitope: an immunodominant region which induces nonreciprocal CTL cross-reactivity.

Authors:  J L Whitton; A Tishon; H Lewicki; J Gebhard; T Cook; M Salvato; E Joly; M B Oldstone
Journal:  J Virol       Date:  1989-10       Impact factor: 5.103

5.  Ebola haemorrhagic fever in Zaire, 1976.

Authors: 
Journal:  Bull World Health Organ       Date:  1978       Impact factor: 9.408

6.  Scheme for ranking potential HLA-A2 binding peptides based on independent binding of individual peptide side-chains.

Authors:  K C Parker; M A Bednarek; J E Coligan
Journal:  J Immunol       Date:  1994-01-01       Impact factor: 5.422

7.  Plaque assay for Ebola virus.

Authors:  J B Moe; R D Lambert; H W Lupton
Journal:  J Clin Microbiol       Date:  1981-04       Impact factor: 5.948

8.  Recombinant RNA replicons derived from attenuated Venezuelan equine encephalitis virus protect guinea pigs and mice from Ebola hemorrhagic fever virus.

Authors:  P Pushko; M Bray; G V Ludwig; M Parker; A Schmaljohn; A Sanchez; P B Jahrling; J F Smith
Journal:  Vaccine       Date:  2000-08-15       Impact factor: 3.641

9.  Human asymptomatic Ebola infection and strong inflammatory response.

Authors:  E M Leroy; S Baize; V E Volchkov; S P Fisher-Hoch; M C Georges-Courbot; J Lansoud-Soukate; M Capron; P Debré; J B McCormick; A J Georges
Journal:  Lancet       Date:  2000-06-24       Impact factor: 79.321

10.  Preparation and use of hyperimmune serum for prophylaxis and therapy of Ebola virus infections.

Authors:  N M Kudoyarova-Zubavichene; N N Sergeyev; A A Chepurnov; S V Netesov
Journal:  J Infect Dis       Date:  1999-02       Impact factor: 5.226

View more
  71 in total

1.  Ebola virus glycoproteins induce global surface protein down-modulation and loss of cell adherence.

Authors:  Graham Simmons; Rouven J Wool-Lewis; Frédéric Baribaud; Robert C Netter; Paul Bates
Journal:  J Virol       Date:  2002-03       Impact factor: 5.103

Review 2.  Filovirus vaccines.

Authors:  Steven B Bradfute; John M Dye; Sina Bavari
Journal:  Hum Vaccin       Date:  2011-06-01

Review 3.  Clinical development of Ebola vaccines.

Authors:  Saranya Sridhar
Journal:  Ther Adv Vaccines       Date:  2015-09

4.  Alphavirus replicon approach to promoterless analysis of IRES elements.

Authors:  K I Kamrud; M Custer; J M Dudek; G Owens; K D Alterson; J S Lee; J L Groebner; J F Smith
Journal:  Virology       Date:  2006-12-06       Impact factor: 3.616

5.  Cellular and humoral immune responses to alphavirus replicon vaccines expressing cytomegalovirus pp65, IE1, and gB proteins.

Authors:  Elizabeth A Reap; Sergey A Dryga; John Morris; Bryan Rivers; Pamela K Norberg; Robert A Olmsted; Jeffrey D Chulay
Journal:  Clin Vaccine Immunol       Date:  2007-04-18

6.  Airway delivery of an adenovirus-based Ebola virus vaccine bypasses existing immunity to homologous adenovirus in nonhuman primates.

Authors:  Jason S Richardson; Stéphane Pillet; Alexander J Bello; Gary P Kobinger
Journal:  J Virol       Date:  2013-01-09       Impact factor: 5.103

7.  A heterologous DNA prime-Venezuelan equine encephalitis virus replicon particle boost dengue vaccine regimen affords complete protection from virus challenge in cynomolgus macaques.

Authors:  Lan Chen; Dan Ewing; Hemavathy Subramanian; Karla Block; Jonathan Rayner; Kimberly D Alterson; Martha Sedegah; Curtis Hayes; Kevin Porter; Kanakatte Raviprakash
Journal:  J Virol       Date:  2007-08-22       Impact factor: 5.103

8.  High prevalence of both humoral and cellular immunity to Zaire ebolavirus among rural populations in Gabon.

Authors:  Pierre Becquart; Nadia Wauquier; Tanel Mahlakõiv; Dieudonné Nkoghe; Cindy Padilla; Marc Souris; Benjamin Ollomo; Jean-Paul Gonzalez; Xavier De Lamballerie; Mirdad Kazanji; Eric M Leroy
Journal:  PLoS One       Date:  2010-02-09       Impact factor: 3.240

Review 9.  Ebola virus vaccines: an overview of current approaches.

Authors:  Andrea Marzi; Heinz Feldmann
Journal:  Expert Rev Vaccines       Date:  2014-02-27       Impact factor: 5.217

10.  Discovery of common marburgvirus protective epitopes in a BALB/c mouse model.

Authors:  Warren V Kalina; Kelly L Warfield; Gene G Olinger; Sina Bavari
Journal:  Virol J       Date:  2009-08-27       Impact factor: 4.099

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.